0
0
9/27/22 at 2:00am
Organization
Mims.com
Author
Audrey Abella
41 words
0
Comments
Reslizumab, a biologic targeting interleukin(IL)-5, reduced severe asthma exacerbation rate and oral corticosteroid (OCS) use in individuals with seve...
You are the first to view
https://specialty.mims.com/topic/add-on-reslizumab-cuts-exacerbations--ocs-use-in-severe-eosinophilic-asthma
Create an account
or login to join the discussion